Advertisement
  1. News
  2. /
  3. Health

Israel study: 4th vaccine shows limited results with omicron

A fourth dose of Pfizer and Moderna only offers “partial defense” against the contagious COVID-19 variant.
N'amah Yetzhak Abohaikal, a volunteer with the women's unit of United Hatzalah emergency service, prepares administer the COVID-19 vaccine to a teen girl as her brother and grandmother watch Tuesday at Clalit Health Services in Mevaseret Zion.
N'amah Yetzhak Abohaikal, a volunteer with the women's unit of United Hatzalah emergency service, prepares administer the COVID-19 vaccine to a teen girl as her brother and grandmother watch Tuesday at Clalit Health Services in Mevaseret Zion. [ MAYA ALLERUZZO | AP ]
Published Jan. 18

JERUSALEM — An Israeli hospital on Monday said preliminary research indicates a fourth dose of the coronavirus vaccine provides only limited defense against the omicron variant that is raging around the world.

Sheba Hospital last month began administering a fourth vaccine to more than 270 medical workers — 154 who received a Pfizer-BioNtech vaccine and 120 others who received Moderna’s. All had previously been vaccinated three times with the Pfizer-BioNtech vaccine.

The clinical trial found that both groups showed increases in antibodies “slightly higher” than following the third vaccine last year. But it said the increased antibodies did not prevent the spread of omicron.

“Despite increased antibody levels, the fourth vaccine only offers a partial defense against the virus,” said Dr. Gili Regev-Yochay, director of the hospital’s infection disease unit. “The vaccines, which were more effective against previous variants, offer less protection versus omicron.”

The preliminary results raised questions about Israel’s decision to offer a second booster shot — and fourth overall — to its over-60 population. The government says over 500,000 people have received the second booster in recent weeks.

Dr. Nahman Ash, director of Israel’s Health Ministry, said the research did not mean the fourth vaccine effort was a mistake. “It returns the level of antibodies to what it was at the beginning of the third booster. That has great importance, especially among the older population,” he told Channel 13 TV.

But he said the research would be taken into account as authorities debate whether to expand the additional booster campaign to the broader population.

Israel was one of the first countries last year to widely vaccinate its population and last summer became the first to offer a booster shot. The latest booster campaign for older Israelis also is believed to be the first of its kind in the world.

Israel’s aggressive vaccination efforts have not been able to stop an omicron outbreak in recent weeks. The variant has caused record-setting infection levels and sent a growing number of people to the hospital, though the numbers of seriously ill remain below previous waves.

It has also forced large numbers of Israelis into quarantine, straining schools and businesses.

Omicron is already dominant in many countries and can also infect those who have been vaccinated or had previously been infected by prior versions of the virus. Early studies, however, show it is less likely to cause severe illness than the previous delta variant. Vaccination and a booster still offer strong protection from serious illness, hospitalization and death.

On Tuesday, the Israeli government said it was shortening the mandatory quarantine period from seven days to five days in order to help keep the economy running.

“This decision will enable us to continue safeguarding public health on the one hand and to keep the economy going at this time on the other, even though it is difficult, so that we can get through this wave safely,” said Prime Minister Naftali Bennett.

Keep up with Tampa Bay’s top headlines

Keep up with Tampa Bay’s top headlines

Subscribe to our free DayStarter newsletter

We’ll deliver the latest news and information you need to know every weekday morning.

You’re all signed up!

Want more of our free, weekly newsletters in your inbox? Let’s get started.

Explore all your options

By Associated Press Writer Josef Federman.

• • •

How to get tested

Tampa Bay: The Times can help you find the free, public COVID-19 testing sites in Citrus, Hernando, Hillsborough, Manatee, Pasco, Pinellas, Polk and Sarasota counties.

Florida: The Department of Health has a website that lists testing sites in the state. Some information may be out of date.

The U.S.: The Department of Health and Human Services has a website that can help you find a testing site.

• • •

How to get vaccinated

The COVID-19 vaccine for ages 5 and up and booster shots for eligible recipients are being administered at doctors’ offices, clinics, pharmacies, grocery stores and public vaccination sites. Many allow appointments to be booked online. Here’s how to find a site near you:

Find a site: Visit vaccines.gov to find vaccination sites in your ZIP code.

More help: Call the National COVID-19 Vaccination Assistance Hotline.

Phone: 800-232-0233. Help is available in English, Spanish and other languages.

TTY: 888-720-7489

Disability Information and Access Line: Call 888-677-1199 or email DIAL@n4a.org.

• • •

More coronavirus coverage

OMICRON VARIANT: Omicron changed what we know about COVID. Here’s the latest on how the infectious COVID-19 variant affects masks, vaccines, boosters and quarantining.

KIDS AND VACCINES: Got questions about vaccinating your kid? Here are some answers.

BOOSTER SHOTS: Confused about which COVID booster to get? This guide will help.

BOOSTER QUESTIONS: Are there side effects? Why do I need it? Here’s the answers to your questions.

PROTECTING SENIORS: Here’s how seniors can stay safe from the virus.

GET THE DAYSTARTER MORNING UPDATE: Sign up to receive the most up-to-date information.

We’re working hard to bring you the latest news on the coronavirus in Florida. This effort takes a lot of resources to gather and update. If you haven’t already subscribed, please consider buying a print or digital subscription.

Advertisement

This site no longer supports your current browser. Please use a modern and up-to-date browser version for the best experience.

Chrome Firefox Safari Edge